BioLife Solutions Exceeds Full Year 2025 Revenue Guidance with Strong Q4 Growth
BLFS sits 34% above its 52-week low of $19.1.
Summary
BioLife Solutions announced preliminary unaudited revenue for Q4 and full year 2025, exceeding its previously raised annual guidance and reporting significant year-over-year growth.
Key Events · Earnings and Guidance · BLFS
-
Exceeded Full Year Revenue Guidance
Preliminary unaudited revenue from continuing operations for 2025 reached $96.2 million, surpassing the high end of the adjusted guidance range of $95.0 million to $96.0 million.
-
Strong Q4 Revenue Growth
Fourth quarter 2025 preliminary revenue from continuing operations was $24.8 million, a 20% increase compared to $20.7 million in the prior year's fourth quarter.
-
Significant Annual Growth
Full year 2025 revenue from continuing operations increased 29% to $96.2 million from $74.6 million in 2024.
-
Positive 2026 Outlook
The company anticipates revenue growth across its product portfolio and further expansion of adjusted EBITDA margin in 2026, with full guidance expected in February.
Analysis · BLFS · Industrial Applications And Services
BioLife Solutions announced preliminary unaudited revenue for Q4 and full year 2025, exceeding its previously raised annual guidance and reporting significant year-over-year growth. The company's preliminary full-year 2025 revenue of $96.2 million surpassed the high end of its adjusted guidance range, indicating strong operational performance. The 20% year-over-year revenue growth in Q4 2025 and 29% for the full year from continuing operations highlight robust demand for its cell processing tools and services. This positive financial update, coupled with the strategic divestitures to become a pure-play cell processing company, positions BioLife Solutions for anticipated profitable growth and margin expansion in 2026.
At the time of this filing, BLFS was trading at $25.65 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $19.10 to $29.62. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.